Morning Overview on MSN
Major review finds limited benefits from new Alzheimer’s drugs hailed as breakthroughs
For the roughly 6.9 million Americans living with Alzheimer’s disease, the arrival of drugs that target amyloid plaques in ...
By Dennis Thompson HealthDay ReporterTHURSDAY, April 16, 2026 (HealthDay News) — New anti-amyloid drugs approved to treat ...
A systematic review suggested that drugs targeting amyloid beta appeared to have no clinically meaningful positive effects, ...
Alzheimer's Society responds to the claim that amyloid-targeting drugs show no clinically meaningful positive effects.
Critics say the meta-analysis provides an inaccurate picture of anti-amyloid medications. Two of them have FDA approval.
Alzheimer’s “wonder drugs” do not work, scientists have found in a study that overturns decades of research into the disease.
The retraction came from Neurobiology of Aging, which removed a 2011 paper claiming to show that a version of a protein ...
A new study has found that combining the current medications for Alzheimer's disease with small molecules derived from ...
The experimental drug lecanemab shows "potential" as an Alzheimer's disease treatment, according to new Phase 3 trial results, but the findings raise some safety concerns because of its association ...
The Alzheimer’s Association offers resources to people diagnosed with Alzheimer’s, as well as loved ones and caretakers. The organization helps patients locate a doctor who fits their needs, provides ...
New Alzheimer's drugs targeting brain amyloid show minimal real-world benefits, a major review found. While plaque reduction ...
Is Alzheimer’s disease a public health crisis yet? Now? Certainly yes for far too many families, but if not today for society in general, the wait will be brief. The Chicago Tribune carried an opinion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results